Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck

Trial Profile

Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Infigratinib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Jun 2018 Planned number of patients changed from 30 to 20.
    • 05 Jun 2018 Planned End Date changed from 1 Jul 2020 to 1 Jun 2025.
    • 05 Jun 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Jun 2025.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top